ESC Premium Access

Comparing clinical outcomes following 1 year of dual antiplatelet therapy in patients risk stratified by the PRECISE-DAPT and DAPT scores

Congress Presentation

About the speaker

Doctor Rene Boudreau

University of Ottawa Heart Institute, Ottawa (Canada)
0 follower

6 more presentations in this session

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-986177/JNJ-70033093, a direct, reversible, small molecule Factor XIa inhibitor in healthy volunteers

Speaker: Doctor V. Perera (Princeton, US)


S62798, a TAFIa inhibitor, accelerates endogenous thrombolysis in a murine model of pulmonary thromboembolism

Speaker: Doctor P. Sansilvestri-Morel (Suresnes, FR)


Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys

Speaker: Doctor P. Wong (Princeton, US)


Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation (TASTER) Study

Speaker: Professor G. Parodi (Sassari, IT)


Adherence to dual anti-platelet therapy after acute coronary syndrome and its impact on patient outcome

Speaker: Doctor P. Sulzgruber (Vienna, AT)


Access the full session

Antithrombotic Therapy Update

Speakers: Doctor R. Boudreau, Doctor V. Perera, Doctor P. Sansilvestri-Morel, Doctor P. Wong, Professor G. Parodi...

About the event


ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb